-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Benzinga·02/02/2026 11:26:21
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.